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Abstract
Background: Knee osteoarthritis (OA) leads to low quality of life due to pain and limitation in daily activities. Recent studies indi-
cated that Methotrexate (MTX) could reduce pain due to its anti-inflammatory effects.
Objectives: In this study, the researchers aimed at evaluating the efficacy of MTX in pain control and improvement of quality of life
in patients with moderate to severe knee OA.
Methods: In this randomized clinical trial, 100 patients with moderate to severe knee OA were allocated to receive MTX (n = 50) 7.5
mg weekly to be increased to 15 mg weekly after first months or placebo (n = 50) for six months. Pain severity was measured using the
numerical rating scale (NRS), so was functional status by Western Ontario and McMaster Universities Arthritis Index (WOMAC) and
quality of life by SF-12 questionnaire before the treatment, and three months and six months after the intervention. The results were
compared between the groups subsequently. Nine patients from the MTX group were excluded due to the use of corticosteroids
during the treatment period.
Results: The MTX group compared to the placebo group had significant improvement in pain severity and quality of life during
six months and WOMAC parameters at three and six months after the intervention. The need for NSAIDS was slightly higher in the
placebo group with no significant difference (22% versus 36%, P = 0.14). The MTX adverse effects were not observed.
Conclusions: Treatment of moderate to severe knee OA with MTX could reduce pain severity and improve functional status and
quality of life in OA patients.
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1. Background
Osteoarthritis (OA) is one of the most common mus-
culoskeletal diseases that could cause pain, joint swelling,
impaired muscular stability, functional disability, and re-
duced quality of life (QOL). In severe cases, there is a loss
of articular cartilage, subchondral bone, and all intra-
articular synovial tissues (1). Knee is the most common
joint that is affected by osteoarthritis (2). Knee OA is the
most common articular disease that leads to an impaired
QOL (3).
The progressive nature of the disease and its associ-
ated pain and disability significantly influences the ability
of the individual to carry out daily activities (4, 5). These
conditions cause pain, reduced function and mobility in
the patient, hence, leads to limitation in activities, such
as walking, climbing stairs, and sitting, bending or lifting;
this results in restrictions in social activities and conse-
quently inevitable impaired QOL (3, 6).
The treatment is usually focused on reducing pain and
improving physical function with multiple drugs, non-
drug, and surgical approaches. Pharmacologic therapies
for pain control in knee OA include topical or oral NSAIDs,
intra-articular injections of corticosteroids, hyaluronate,
and opioids, and modulators of osteoarthritis, including
glucosamine compounds (7). The proper treatment with
minimal side effects and acceptable efficacy is still not de-
fined.
Magnetic resonance imaging (MRI) studies have
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shown that synovitis is very common in knee OA and is
associated with the related pain and its severity (8-11).
Methotrexate (MTX) is an effective and commonly used
disease-modifying agent for inflammatory arthritis with
favorable long-term results (12). A few studies have ad-
dressed low-dose MTX in OA (13-15), each with different
outcomes. Considering the effects of MTX in the treatment
of inflammatory arthritis and the role of inflammation
in OA, it seems that MTX use in the treatment would be
beneficial.
2. Objectives
This study aimed at evaluating the effects of MTX on the
control of pain and improvement of QOL in patients with
moderate to severe knee OA.
3. Methods
In this randomized placebo-controlled clinical trial,
100 patients with moderate to severe OA visiting rheuma-
tology clinics were recruited. Patients between 45 and 75
years of age with moderate to severe knee OA with non-
inflammatory joint effusions according to fluid analysis,
who were able to walk with peripheral knee pain and who
scored more than five by numerical rating scale (NRS) or
more than 48 by WOMAC were included in the study. The
patients had radiographic evidence of OA with Kellgren-
Lawrence score of III to IV (moderate to severe) on x-ray. Ex-
clusion criteria were having other rheumatologic disease,
other knee or periarticular disease, lower limbs fracture
with knee joint involvement, OA of the hip and ankle, his-
tory of knee surgery or trauma, radicular pain, intraartic-
ular corticosteroid injection or physiotherapy in the pre-
vious three months and hyaluronic injection in the previ-
ous six months, psychiatric disorders, balance, neurologic
sensory and/or neurologic deficit, and patients with any
type of malignancy. This research also excluded patients
with underlying systemic disease, such as renal, hepatic or
heart failure, uncontrolled blood pressure, diabetes melli-
tus, and severe asthma in need of corticosteroids use. Pa-
tients with corticosteroids use in the last six weeks prior
to the study and those with allergic reactions to MTX or
its derivatives were also excluded. The ethics committee of
Ardabil University of Medical Sciences approved the study
protocol (approval number: IR.ARUMS.REC.1396.150) and
registered at the Iranian Registry of Clinical Trials under
the code of IRCT20170716035126N1; informed consent was
obtained from all of the individuals.
The study sample size for each group was calculated
as 44 cases considering an effect size of d ≥ 0.60 as sta-
tistically significant in a two-tailed test with α = 0.05 and
power of 0.90. As there was possibility that some patients
do not complete the study, the researchers included 50 pa-
tients in each group. Using random number blocks and
sealed envelopes, patients were enrolled in the study ac-
cording to the sample size (Figure 1). All patients com-
pleted the study period yet nine patients in the MTX group
were excluded from the final analysis as all of them in the
last visit reported corticosteroid use during the study pe-
riod.
In both groups, glucosamine sulfate 1500 mg daily was
administered; as well as, MTX 7.5 mg (three pills) weekly
with subsequent increase to 15 mg weekly after the first
month in the intervention group or placebo, three pills
weekly in the control group with subsequent increase to
six pills after the first month. All patients in both groups
also received folic acid 1 mg daily. The total treatment pe-
riod was six months. Participants and the physician assess-
ing the outcome of the study were blinded to the allocated
groups.
Before the study, after the first month, and then every
three months, blood samples were obtained from all pa-
tients to measure complete blood cell count, liver func-
tion tests, blood urea nitrogen, and creatinine for possi-
ble change in their values and any contraindication for
MTX use or its dosage adjustment. The researchers mea-
sured common side effects of MTX as decrease in blood
counts, gastrointestinal complications (nausea, vomiting,
diarrhea, and mouth ulcers) and increase in liver enzyme
and hepatitis.
Patients were allowed to use NSAIDS only in the first
three months until the MTX effect occurred and were pro-
hibited to use corticosteroids at any time during the study
period.
The study outcome was measured before, at three
months, and six months after the intervention. During
these periods, pain severity, functional status, and qual-
ity of life were measured using the NRS, WOMAC, and SF-
12 questionnaire, respectively. The NRS is the simplest and
most commonly used numeric scale, in which the patient
rates pain from 0 (no pain) to 10 (worst pain).
The WOMAC questionnaire includes 24 questions that
measure the three dimensions of pain (five items), stiffness
(two items), and physical function (17 items). Each ques-
tion is based on a five-point Likert scale resulting in total
number range of 0 to 96. With increase in the severity of
the disease, the points are increased (16). The Persian for-
mat of the WOMAC questionnaire was validated previously
(17).
The SF-12 questionnaire is the short form of SF-36 Qual-
ity of Life (QOL) questionnaire, which is widely used to
measure QOL in different diseases. Due to the small num-
ber of items, the overall score is often used. The question-
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Figure 1. CONSORT flow diagram of the study
naire examines the QOL in terms of overall understanding
of their health, physical functioning, physical health, emo-
tional problems, physical pain, social function, vitality, and
mental health. Montazeri et al. (18) evaluated validity and
reliability of the Persian version of SF-12 among the Iranian
population.
3.1. Statistical Analysis
All data were analyzed using SPSS 20 (version 22; SPSS
Inc., Chicago, IL). The results are expressed as mean± stan-
dard deviation or percentage. Kolmogorov-Smirnov test
was used to assess the normal distribution of data. Chi
square test, Fisher’s exact test, independent t-test or Mann-
Whitney U test were used to compare data between groups.
Repeated measure analysis of variance (ANOVA) was used
to compare serial changes in parameters during the study
period in each and between groups. P values of less than
0.05 were considered statistically significant.
4. Results
Both groups were comparable regarding demographic
and baseline clinical data (Table 1).
The two groups were also comparable regarding pain
score according to NRS before the intervention (7.65± 1.21
in MTX versus 7.46 ± 1.38 in placebo, P = 0.47). After the
intervention, there was a significant serial reduction in
NRS score (Figure 2) with no difference in NRS after three
months between groups (P = 0.052) and with final NRS of
4.09± 1.24 versus 5.30± 1.56 in MTX and placebo groups,
respectively. The MTX group had significantly greater re-
duction in NRS than the placebo group (P < 0.001).
The total WOMAC and its subscales before, at three
months, and six months after the intervention are shown
in Table 2. Before the intervention, there was no significant
difference between groups, while during the three months
and six months evaluations, total and its subscales scores
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Table 1. Demographic and Baseline Clinical Data Od Study Groupsa
Methotrexate, (N = 41) Placebo, (N = 50) P Value
Age, y 53.75± 6.59 52.42± 7.19 0.31
Gender 0.89
Male 15 (36.6) 19 (38)
Female 26 (63.4) 31 (62)
Disease duration, y 8.34± 3.63 7.16± 4.11 0.15
Kellgren-Lawrence score 0.31
III 21 (51.2) 31 (62)
IV 20 (48.8) 19 (38)
aValues are expressed as mean± SD or No. (%).
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Figure 2. NRS changes during the study in both groups
were significantly lower in the MTX group as compared to
the placebo group. Evaluating the serial changes between
groups also showed significant improvement in the total
WOMAC and its subscales in the MTX group as compared
to the placebo.
The two groups had similar SF-12 score before the in-
tervention, yet there was significantly higher SF-12 score in-
dicative of better QOL at six months, yet not three months
after the intervention in the MTX group (Table 3). The serial
changes were also significantly better in the MTX group (P
< 0.001).
During the study period, nine patients (22%) from MTX
group and 18 patients (36%) from placebo group used
NSAIDS and analgesics for pain reduction with no signifi-
cant difference between the groups (P = 0.14).
No patients reported MTX side effects.
5. Discussion
This study examined the efficacy of MTX in controlling
pain and QOL in patients with moderate to severe knee OA.
The results of this study showed a significant reduction in
pain intensity in patients based on NRS and pain subscales
of WOMAC, along with improved QOL following treatment
with MTX for six months.
Pavleka et al. (14) in their study on the treatment of ero-
sive hand OA showed a marked decrease in pain intensity
following treatment with 10 mg MTX, weekly. Wenham et
al. (15) in their study on 30 patients with knee OA treated
with an initial dose of weekly MTX 7.5 mg and subsequent
increase up to 20 mg weekly for 24 weeks, showed a signifi-
cant pain reduction in almost 60% of the patients, while in
13% of the patients, the symptoms were worsened. Unlike
these studies, Holanda et al. (13) found no statistically sig-
nificant difference in pain intensity based on VAS between
patients treated with 7.5 mg MTX weekly or placebo.
Kingsbury et al. (19) previously published a detailed
description of a Phase III trial on the effectiveness of MTX
on 160 patients with knee OA; although researchers com-
pleted the recruitment phase, no research results have
been provided yet.
Differences in study sample size, inclusion and exclu-
sion criteria, and MTX dosage used in various studies can
somehow justify differences between studies. It can be con-
cluded that MTX at higher doses has the ability to control
pain in patients with moderate to severe knee OA. Since
the results of the Kingsbury et al. study have not been re-
ported yet, the present study had the highest sample size
compared to the other studies, with acceptable results.
This study used the WOMAC questionnaire for better
evaluation of the MTX efficacy during the intervention. The
results showed a more significant decrease in the overall
WOMAC score and its subscales of pain and physical func-
tion in the MTX group compared to the placebo group.
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Table 2. WOMAC Total Score and its Subscales Before, Three Months, and Six Months After the Intervention Between the Groupsa
Methotrexate Group, (N = 41) Placebo Group, (N = 50) P Value
WOMAC total
Before 64.46± 4.60 66.16± 5.64 0.12
3 months after 57.56± 6.12 65.60± 8.29 < 0.001b
6 months after 38.46± 4.24 57.82± 7.12 < 0.001b
WOMAC Subscales
Pain
Before 13.19± 1.52 13.88± 2.00 0.07
3 months after 11.65± 1.40 13.76± 2.21 < 0.001b
6 months after 8.00± 2.56 12.84± 1.96 < 0.001b
Stiffness
Before 5.51± 0.92 5.66± 1.11 0.50
3 months after 4.63± 1.44 5.38± 0.98 0.004b
6 months after 4.63± 1.44 5.40± 0.96 0.004b
Physical function
Before 45.75± 3.91 46.62± 5.62 0.4
3 months after 41.26± 5.03 46.44± 6.56 < 0.001b
6 months after 27.02± 3.45 39.90± 5.80 < 0.001b
Abbreviation: WOMAC, western ontario and mcmaster universities arthritis index.
aValues are expressed as mean± SD.
bP is two-sided significant.
Table 3. SF-12 Score Before, Three Months and Six Months After the Intervention Be-
tween Groupsa
SF-12 Score Methotrexate
Group, (N = 41)
Placebo Group,
(N = 41)
P Value
Before
intervention
19.48± 1.58 19.06± 1.82 0.24
Three months
after
24.17± 2.50 23.28± 2.17 0.07
Six months after 29.24± 2.77 24.96± 4.38 < 0.001b
aValues are expressed as mean± SD.
bP is two-sided significant.
Similarly, Wenham et al. (15) found a significant im-
provement in physical function and a significant reduc-
tion in pain severity three months and six months after the
treatment, respectively. However, there was no significant
improvement in physical function after the third month as
compared to six month after treatment. In Holanda et al.’s
study (13) there was no significant difference between the
two groups in terms of the WOMAC score. In contrast, the
researchers observed a significant decrease in overall score
and in both pain and physical function subscales following
treatment with MTX.
The NRS is a one-dimensional scale, which evaluates
the severity of pain from the perspective of the patient at
the time of assessment. On the other hand, WOMAC con-
sists of three subscales including pain, stiffness, and physi-
cal function with questions covering daily activities. There-
fore, the evaluation by the WOMAC scale seems to be more
comprehensive. Due to the reduction in the intensity of
pain and the improvement of the WOMAC physical func-
tion, MTX may be useful in treating moderate to severe
knee OA.
The QOL of patients with knee OA is directly related to
the severity of their pain and therefore, it is expected that
pain relief would improve their QOL. In a study by Manoy
et al. (20) a significant decrease in the pain intensity of
knee OA patients after treatment with vitamin D was re-
ported, which was accompanied by improved QOL based
on the SF-12 questionnaire. In the present study, there was
a significant improvement in patients’ QOL based on SF-12
questionnaire at the end of six months in the group treated
with MTX.
The researchers found no significant difference in the
number of NSAIDs used between the two groups, although
there was a lower tendency for consumption in the MTX
group. Holand and colleagues (13) also did not report any
significant differences between MTX and placebo groups
Anesth Pain Med. 2019; 9(3):e89990. 5
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in terms of paracetamol consumption, although there was
a tendency to consume more paracetamol in the placebo
group.
Furthermore, a relative improvement in the severity
of pain and total WOMAC and its subscales score were
observed in the placebo group following the treatment,
which could be explained by the placebo effect, the role of
empathy in treatment, and the effect of concurrent treat-
ment with glucosamine (although controversial), rather
than the chance factor.
In addition, although not considered in this study, ap-
propriate health care and preventive measures, such as
proper diet, exercise and weight loss, can contribute to the
improvement of symptoms in the placebo group.
Several studies have assessed the effect of weight loss
and physical function on knee OA patients (21-23). Weight
loss using aerobic exercises as well as proper diet are rec-
ommended in guidelines for knee OA patients. A review
study concluded that weight loss results in pain relief and
functional improvement in elderly patients with knee OA
(22).
Knee OA is common among elder populations, whom
would have comorbidities and the medications used
would have more complications and side effects. There-
fore, it is important to ensure safety of drugs before admin-
istration and choose options with minimum or no side ef-
fects and with long-term benefits (24). Furthermore, MTX
is well tolerated for long term use and concomitant folic
acid use reduces side effects (19). As the researchers ob-
served no significant side effects of MTX use during the
study period, along with its efficacy in reducing pain and
improving QOL, it seems a suitable medication for knee OA.
The strength of this study can be attributed to its ran-
domized clinical trial design and its prospective nature.
However, this study also has some limitations, including
but not limited to sample size of the study (although
higher than the other studies), the duration of the study,
and the lack of patient follow up after the completion of
the treatment. Although nine patients from the MTX group
were excluded from the study due to corticosteroid use,
which can be indicative of a selection bias during sampling
process, yet all these nine patients had moderate knee OA
and were not those with severe OA.
5.1. Conclusions
Treatment of moderate to severe knee OA with MTX
could reduce pain severity and improve functional status
and quality of life in such patients.
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